Shared in Mesoblast dropped on the last day of August 2021 after the Melbourne-based biotech was told that the company’s investigational respiratory treatment for Covid-19 needed to undergo another trial in order to receive emergency use authorization (EUA) from U.S. Food and Drug Administration.

Shares of bluebird bio were down more than 24 percent after the company announced that the U.S. Food and Drug Administration placed a clinical hold on studies of the gene therapy elivaldogene autotemcel (eli-cel) for cerebral adrenoleukodystrophy (CALD).

Massachusetts-based biotechnology firm Biogen and its Tokyo-based partner Eisai are seeking a speedy approval from the U.S. Food and Drug Administration for a second Alzheimer’s disease drug, lecanemab. 

Eli Lilly is in the news for positive Olumiant data in Covid-19, a drop in Covid-19 product sales for second-quarter 2021, and a protest of one of the company’s ads.

AbbVie’s Rinvoq continues to demonstrate the medicine’s clinical potential to become the heir-apparent to the company’s blockbuster drug Humira, which will lose patent protection in 2023. In the company’s second-quarter 2021 report, AbbVie touted advances Rinvoq made throughout the three months, including positive Phase III data in ulcerative colitis.

Gilead Sciences will open the doors to the company’s new operations site in North Raleigh, N.C., as part of a business services center expansion. Gilead’s second-quarter 2021 product sales increased 21 percent year-over-year, primarily driven by the Covid-19 antiviral treatment Veklury (remdesivir).

Second-quarter 2021 sales of AstraZeneca’s Covid-19 vaccine more than tripled to $894 million from the first quarter, but the drugmaker on July 29 again delayed the U.S. application for approval as the company gathers more data for submissions.

Pfizer Inc. on July 28 raised the 2021 sales forecast for the company’s Covid-19 vaccine by 29 percent to $33.5 billion, and said the drugmaker believes people will need a third dose of the shot developed with German partner BioNTech to keep protection against the virus high.

One month after GlaxoSmithKline outlined plans for the company’s future following a planned split between its pharmaceuticals and consumer health businesses, GSK posted second-quarter 2021 sales of £8.1 billion ($11.2 billion).

Bristol Myers Squibb Co. reported second-quarter 2021 earnings that topped Wall Street estimates, as sales of the company’s flagship cancer treatment Opdivo returned to growth after missing estimates in the previous quarter.